铂类抗癌药物在妇科肿瘤治疗中的应用效果及安全性观察

Observation of the effect and safety of platinum-based anticancer drugs in the treatment of gynecological tumors

目的 观察铂类抗癌药物在妇科肿瘤治疗中的应用效果及不良反应发生情况。方法 60例妇科肿瘤患者,按照抽签法随机分为干预组和对照组,每组30例。干预组患者选择顺铂联合紫杉醇药物治疗,对照组患者选择卡铂联合紫杉醇药物治疗。对比两组患者的临床疗效、不良反应发生情况及治疗前后生活质量评分。结果 干预组患者总有效率为93.33%,与对照组的90.00%对比差异无统计学意义(P>0.05)。干预组患者用药不良反应发生率为20.00%,与对照组的23.33%对比差异无统计学意义(P>0.05)。治疗前,干预组生理机能、生理职能、躯体疼痛、一般健康状况、精力、社会功能、情感职能以及精神健康评分分别为(58.97±6.09)、(61.42±5.63)、(51.93±5.93)、(48.73±5.62)、(53.34±5.84)、(50.67±5.30)、(55.74±5.58)、(48.95±6.76)分,对照组分别为(59.56±5.84)、(61.57±4.35)、(51.34±5.42)、(48.67±5.45)、(53.54±5.47)、(51.71±4.98)、(55.24±5.46)、(48.37±6.61)分;治疗后,干预组生理机能、生理职能、躯体疼痛、一般健康状况、精力、社会功能、情感职能以及精神健康评分分别为(68.54±6.12)、(76.53±6.41)、(66.53±6.31)、(70.04±5.94)、(61.81±5.96)、(60.48±6.39)、(62.83±6.51)、(58.73±5.36)分,对照组分别为(68.37±5.34)、(75.87±6.92)、(66.85±5.27)、(69.17±5.46)、(61.73±5.21)、(59.87±5.73)、(62.91±5.58)、(58.76±5.54)分。治疗后,两组患者生理机能、生理职能、躯体疼痛、一般健康状况、精力、社会功能、情感职能以及精神健康评分均高于本组治疗前,差异具有统计学意义(P<0.05)。结论 卡铂、顺铂等铂类抗癌药物应用于妇科肿瘤治疗中疗效显著,均能有效改善患者的临床症状与病情,提升生活质量,且不良反应较少,安全性较高,值得推广应用。

Objective To observe the effect and adverse reactions of platinum-based anticancer drugs in the treatment of gynecological tumors.Methods A total of 60 patients with gynecological tumors were randomly divided into intervention group and control group according to the lottery method,with 30 cases in each group.Patients in the intervention group were treated with cisplatin and paclitaxel,and patients in the control group were treated with carboplatin and paclitaxel.The clinical efficacy,occurrence of adverse reactions,and quality of life scores before and after treatment were compared between the two groups.Results The total effective rate of the intervention group was 93.33%,and the difference was not statistically significant when compared with 90.00%in the control group(P>0.05).The incidence of adverse drug reactions in the intervention group was 20.00%,and the difference was not statistically significant when compared with 23.33%in the control group(P>0.05).Before treatment,the scores of physical functioning,role-physical,bodily pain,general health status,vitality,social functioning,role-emotional and mental health were(58.97±6.09),(61.42±5.63),(51.93±5.93),(48.73±5.62),(53.34±5.84),(50.67±5.30),(55.74±5.58)and(48.95±6.76)points in the intervention group,and(59.56±5.84),(61.57±4.35),(51.34±5.42),(48.67±5.45),(53.54±5.47),(51.71±4.98),(55.24±5.46)and(48.37±6.61)points in the control group.After treatment,the scores of physical functioning,role-physical,bodily pain,general health status,vitality,social functioning,role-emotional and mental health were(68.54±6.12),(76.53±6.41),(66.53±6.31),(70.04±5.94),(61.81±5.96),(60.48±6.39),(62.83±6.51)and(58.73±5.36)points in the intervention group,and(68.37±5.34),(75.87±6.92),(66.85±5.27),(69.17±5.46),(61.73±5.21),(59.87±5.73),(62.91±5.58)and(58.76±5.54)points in the control group.After treatment,the scores of physical functioning,role-physical,bodily pain,general health status,vitality,social functioning,role-emotional and mental health in both groups were higher than those before treatment in this group,and the differences were statistically significant(P<0.05).Conclusion Platinum-based anticancer drugs such as carboplatin and cisplatin have significant efficacy in the treatment of gynecological tumors,which can improve the clinical symptoms and conditions of patients,improve their quality of life,with fewer adverse reactions and higher safety.It is worthy of promotion and application.